Rosso R, Nobile M T, Sertoli M R, Giannitelli A, Santi P L, Volpe R, Nicolò G
Oncology. 1985;42(2):86-8. doi: 10.1159/000226006.
Human fibroblast interferon was given intranodularly to 14 patients with cutaneous metastases from breast cancer and malignant melanoma; 1,000,000 units/cm3 of tumor tissue was administered daily for 8-10 days. 13 patients were evaluated. Complete response was achieved in 1 of 7 breast carcinoma nodules and in 2 of 6 melanoma nodules; partial response was achieved in 1 of 7 breast carcinoma and in 3 of 6 melanoma nodules. The overall objective response was therefore 7 of 13 (53.8%) metastatic nodules. Pathological complete response was confirmed in 2 of 3 complete clinical responses. Necrosis, lymphocytic infiltration and fibrosis were observed in all the specimens pathologically examined. In spite of a clear antitumoral activity, this approach does not appear to have clinical significance due to its extremely localized effect.
将人成纤维细胞干扰素经瘤内注射给予14例患有乳腺癌和恶性黑色素瘤皮肤转移的患者；每天以100万单位/立方厘米的肿瘤组织剂量给药，持续8 - 10天。对13例患者进行了评估。7个乳腺癌结节中有1个、6个黑色素瘤结节中有2个达到完全缓解；7个乳腺癌结节中有1个、6个黑色素瘤结节中有3个达到部分缓解。因此，13个转移结节中的总体客观缓解率为7个（53.8%）。3例临床完全缓解中有2例经病理证实为病理完全缓解。在所有经病理检查的标本中均观察到坏死、淋巴细胞浸润和纤维化。尽管具有明显的抗肿瘤活性，但由于其作用极为局限，这种方法似乎没有临床意义。
